EXICURE, INC. Litigation Settlement, Expense
EXICURE, INC. (XCUR) reported Litigation Settlement, Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2026-03-25
- EXICURE, INC. litigation settlement, expense for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. litigation settlement, expense for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- EXICURE, INC. litigation settlement, expense for the quarter ending 2024-12-31 was $424.00K, a 54.80% decline year-over-year.
- EXICURE, INC. litigation settlement, expense for the quarter ending 2024-09-30 was $1.14M.
- EXICURE, INC. litigation settlement, expense for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EXICURE, INC. litigation settlement, expense for fiscal 2024 was $1.56M, a 66.52% increase from fiscal 2023.
- EXICURE, INC. litigation settlement, expense for fiscal 2023 was $938.00K.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||
| 2024-12-31 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.56M derived: sum of 2 quarters · filed 2026-03-25 | $1.56M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $1.14M 10-Q · filed 2025-11-07 | $1.14M 10-Q · filed 2025-11-07 | ||
| 2023-12-31 | $938.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $938.00K derived: sum of 2 quarters · filed 2025-03-18 | $938.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |